Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...
Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...
The headline trial results will be closely monitored by pharmaceutical industry experts. Shares in Novo Nordisk, which ...
Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...
Hosted on MSN6d
Is Viking Therapeutics a Buy on the Dip?Market leaders Novo Nordisk and Eli Lilly First, let's consider some ... 100-milligram doses are both impressive, and the ...
Investor's Business Daily on MSN5d
Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity ShotAmgen stock tumbled late Tuesday on a report that its high-profile weight-loss shot, MariTide, could be linked to bone ...
There aren't many biotechs that are more exciting than Viking Therapeutics ( VKTX -7.45%) right now. Thanks to its clinical-stage candidate for weight loss, there's a real chance that this competitor ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
Therapeutic strides in biotech are advancing promising candidates in clinic to address different stages of sleep apnea and ...
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback